Docetaxel emulsion - Savara Pharmaceuticals

Drug Profile

Docetaxel emulsion - Savara Pharmaceuticals

Alternative Names: ANX-514; BTH-014; Polysorbate 80-free formulation of docetaxel - Savara Pharmaceuticals; SDP-014

Latest Information Update: 03 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADVENTRX Pharmaceuticals
  • Developer Mast Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Apr 2017 Mast Therapeutics merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
  • 19 Jul 2013 Biomarkers information updated
  • 11 Mar 2013 ADVENTRX is now called Mast Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top